Search results for "Macroglobulin"

showing 10 items of 20 documents

Rat hepatocytes in primary culture synthesize and secrete cellular fibronectin

1992

Fibronectins, involved in cell-matrix interactions and cell attachment, are glycoproteins which show a remarkable heterogeneity, due to alternative splicing. The type III-related domains, ED-A and ED-B, are present in cellular fibronectin in a variety of ratios whereas they are absent in circulating plasma fibronectin. Fibronectin synthesis by hepatocytes which are accepted as suppliers of plasma fibronectin was studied in primary cultures during a 6-day culture period. Using site-specific antibodies we demonstrate that rat hepatocytes are also able to synthesize and secrete fibronectin bearing the ED-A domain from Day 3 on after inoculation. By immunocytological characterization of the hep…

Fluorescent Antibody TechniqueDexamethasoneLamininmedicineAnimalsalpha-MacroglobulinsRNA MessengerRats WistarCells Culturedchemistry.chemical_classificationMessenger RNAbiologyCell BiologyBlotting NorthernFNDC5Molecular biologyFibronectinsFibronectinsRatsFibronectinmedicine.anatomical_structureLiverchemistryCell cultureHepatocytebiology.proteinGlycoproteinExperimental Cell Research
researchProduct

The Spectrum of Ocular Manifestations in Patients with Waldenström's Macroglobulinemia.

2021

Purpose: To investigate the ocular manifestations in 91 Waldenstrom's macroglobulinemia (WM) patients.Methods: Retrospective, cross-sectional, observational analysis.Results: Ocular impairments, detected in 19 patients, included flame-shaped hemorrhages, venous sausaging, papilledema, macular detachments, or central retinal vein occlusion in 16 patients; paraproteinemic keratopathy in 2; and a CANOMAD syndrome in 1. Best-corrected visual acuity was ≥0.5 logMAR units in 11 of 38 eyes. Intraocular pressure was increased in seven eyes. Genetic analysis in seven patients showed a mutation in the MYD88 gene in six patients and a nonsense mutation in the CXCR4 gene in five patients. Plasmapheresi…

Intraocular pressuremedicine.medical_specialtyVisual acuitygenetic structuresmedicine.medical_treatment03 medical and health sciences0302 clinical medicineCentral retinal vein occlusionOphthalmologymedicineImmunology and AllergyPapilledemabusiness.industryMacroglobulinemiamedicine.diseaseeye diseases3. Good healthOphthalmology030220 oncology & carcinogenesis030221 ophthalmology & optometryRituximabPlasmapheresismedicine.symptombusinessmedicine.drugRetinopathyOcular immunology and inflammation
researchProduct

Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment acco…

1984

The thrombocyte count, the factor XIII (F XIII) activity, the concentration of fibrinogen (F I), prothrombin (F II), fibronectin (CIG), albumin and the proteinase inhibitors antithrombin III (AT III), alpha 2-macroglobulin (A2M), alpha 1-antitrypsin (A1A) and Cl-esterase inactivator (Cl-INA) were determined in ten children with acute lymphoblastic leukaemia (ALL). Changes due to the disease and to therapy were observed. Before the start of treatment the patients had thrombocytopenia secondary to the disease, and the proteinase inhibitors--especially Cl-INA and A1A--were raised. During the induction phase the thrombocyte count rose but there was also a marked increase in the concentration of…

Malemedicine.medical_specialtyAdolescentAntithrombin IIIAlpha (ethology)Complement C1 Inactivator ProteinsFibrinogenMaintenance therapyInternal medicineDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProtease Inhibitorsalpha-MacroglobulinsChildGenetics (clinical)Factor XIIIbusiness.industryAntithrombinAlbuminFibrinogenGeneral MedicineFactor XIIIMolecular medicineBlood Coagulation FactorsFibronectinsLeukemia LymphoidEndocrinologyCoagulationChild Preschoolalpha 1-AntitrypsinImmunologyMolecular MedicineFemaleProthrombinbusinessmedicine.drugKlinische Wochenschrift
researchProduct

Rheopheresis in Patients with Critical Limb Ischemia--Results of an Open Label Prospective Pilot Trial

2005

Rheopheresis is a specifically designed application of double filtration plasmapheresis, for extracorporeal treatment of microcirculatory disorders. Safety and efficacy of Rheopheresis for wound healing and skin oxygenation were investigated in patients with critical limb ischemia. Twelve patients of Fontaine stage III-IV were treated with a series of 10 Rheopheresis sessions over 17 weeks. Transcutaneous oxygen pressure (tcpO(2)) and ankle-brachial index (ABI) were repeatedly determined to monitor the effects of the Rheopheresis treatment series on microcirculation and skin blood flow. Laboratory parameters of blood rheology were measured in addition to safety parameters and course of the …

Malemedicine.medical_specialtymedicine.medical_treatmentRheopheresisPilot ProjectsExtracorporealMicrocirculationIschemiamedicineHumansalpha-MacroglobulinsProspective StudiesProspective cohort studyAgedSkinWound Healingbusiness.industryFibrinogenProteinsCholesterol LDLPlasmapheresisHematologyCritical limb ischemiaOxygenationMiddle AgedSurgeryClinical trialTreatment OutcomeImmunoglobulin MLower ExtremityAmputationRegional Blood FlowNephrologyFemalemedicine.symptombusinessBlood Gas Monitoring TranscutaneousTherapeutic Apheresis and Dialysis
researchProduct

A case of Waldenstroem's disease with a monoclonal IgM antiphospholipid antibody

2002

The antiphospholipid syndrome (APS) was described in 1983 as a clinical entity characterized by venous and arterial thrombosis, thrombocytopenia, and recurrent fetal loss. The serological markers of APS are antiphospholipid antibodies (APLA) directed mainly against anionic phospholipids, usually cardiolipin but also phosphatidylserine. Some APLA exhibit lupus anticoagulant activity. Monoclonal gammopathy sometimes occurs with the presence of autoantibodies. In this paper, we describe a patient with the diagnosis of immunocytoma with an IgM, kappa paraprotein with apparent specificity against anionic phospholipids, and lupus anticoagulant activity, but no clinical signs of APS. We describe i…

Pathologymedicine.medical_specialtyImmunologymedicine.disease_causeSerologyAutoimmunityImmunoglobulin kappa-ChainsRheumatologyimmune system diseasesAntiphospholipid syndromemedicineHumansImmunology and AllergyGlycoproteinsLupus anticoagulantbiologybusiness.industryAutoantibodyWaldenstrom macroglobulinemiaMiddle Agedmedicine.diseaseTreatment OutcomeImmunoglobulin Mbeta 2-Glycoprotein ILupus Coagulation InhibitorImmunologyMonoclonalAntibodies Antiphospholipidbiology.proteinFemaleWaldenstrom MacroglobulinemiaAntibodybusinessParaproteinsRheumatology International
researchProduct

Clinical disorders responsible for plasma hyperviscosity and skin complications

2017

In this brief review, we have examined some clinical disorders which are associated to an altered hemorheological profile and at times accompanied by skin ulcers. This skin condition may be, in fact, observed in patients with primary plasma hyperviscosity such as multiple myeloma, Waldenstrom macroglobulinemia, cryoglobulinemia, cryofibrinogenemia, dysfibrinogenemia and connective tissue diseases. It must be underlined that the altered hemorheological pattern is not the only responsible for this skin complication but, as it worsens the microcirculatory flow, it contributes to determine the occurrence of the skin ulcers.

Pathologymedicine.medical_specialtyParaproteinemiasCryofibrinogenemiaHyperviscosityConnective tissuePlasma hyperviscosity030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesWhole-blood viscositySkin UlcerInternal MedicinemedicineHumansDysfibrinogenemiaConnective Tissue DiseasesMultiple myeloma030203 arthritis & rheumatologyintegumentary systembusiness.industryMicrocirculationDisease ManagementWaldenstrom macroglobulinemiaSyndromeBlood Viscositymedicine.diseaseCryoglobulinemiaDermatologymedicine.anatomical_structureCryoglobulinemiaWaldenstrom MacroglobulinemiaMultiple MyelomaComplicationbusinessEuropean Journal of Internal Medicine
researchProduct

Cultured Ito cells of rat liver express the alpha 2-macroglobulin gene.

1987

Ito cells were isolated from rat liver and kept in culture for up to 13 days. The capability of the Ito cells to synthesize a2-macroglobulin was analyzed at different times after isolation and by pulse-chase experiments. Newly synthesized a2-macroglobulin was determined by immunoprecipitation followed by sodium dodecyl sulfate/ polyacrylamide gel electrophoresis and fluorography. a2-Macroglobulin synthesis was hardly detectable in Ito cells and their media 3 days after plating. However, 5 - 11 days after the isolation of the cells, increasing amounts of a2-macroglobulin were synthesized. The results of pulse-chase experiments performed on day 7 showed that radioactively labeled a2-macroglob…

Time FactorsBiologydigestive systemBiochemistrychemistry.chemical_compoundfluids and secretionsAnimalsalpha-MacroglobulinsNorthern blotRNA MessengerSodium dodecyl sulfatePancreatic elastasePolyacrylamide gel electrophoresisCells CulturedImmunoassayDNALipid MetabolismMolecular biologyMacroglobulinRatsSecretory proteinPerisinusoidal spaceBiochemistrychemistryGene Expression RegulationLiverHepatic stellate cellElectrophoresis Polyacrylamide GelFemalecirculatory and respiratory physiologyEuropean journal of biochemistry
researchProduct

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patie…

2004

Abstract Lymphomplasmocytoid/ic immunocytoma (LP-IC), including Waldenstrom’s macro-globulinemia and lymphoplasmacytoid lymphoma according to the Kiel classification (the latter one subsummed as a variant of B-CLL in the WHO classification), is an indolent lymphoma, which is incurable by conventional chemotherapy in the advanced stage of disease. The anti-CD20 antibody Rituximab has shown remarkable activity in indolent lymphomas, in particular when combined with chemotherapy. Based on these results the GLSG investigated the efficacy of a combined immuno-chemotherapy (R-CHOP: Rituximab 375 mg/m2 d0-1; cyclophosphamide 750 mg/m2 d1; doxorubicine 50 mg/m2 d1; vincristine 1.4 mg/m2 d1; prednis…

Vincristinemedicine.medical_specialtyCyclophosphamideImmunologyCHOPBiochemistryGastroenterologyLymphoplasmacytic Lymphoma03 medical and health sciences0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicine030304 developmental biology0303 health sciencesbusiness.industryWaldenstrom macroglobulinemiaCell BiologyHematologymedicine.disease3. Good healthSurgeryLymphomaRegimen030220 oncology & carcinogenesisRituximabbusinessmedicine.drugBlood
researchProduct

Feedback Mechanisms between ?2M and TGF?1 Reduce Extracellular Matrix Synthesis of Liver Fat-Storing Cells

1994

biologyChemistrybusiness.industryGeneral NeuroscienceTransforming growth factor betaFibronectinsGeneral Biochemistry Genetics and Molecular BiologyExtracellular MatrixFibronectinsCell biologyExtracellular matrixText miningLiverHistory and Philosophy of ScienceTransforming Growth Factor betaAlpha macroglobulinsLiver fatAdipocytesbiology.proteinProteoglycansalpha-MacroglobulinsbusinessAnnals of the New York Academy of Sciences
researchProduct

A new hepatocyte stimulating factor: cardiotrophin-1 (CT-1)

1995

Abstract Recently, a novel cytokine, cardiotrophin-1 (CT-1), was cloned and found to induce cardiac myocyte hypertrophy in vitro. Amino acid sequence similarity showed CT-1 to be a member of the IL-6/LIF/CNTF/OSM/IL-11 cytokine family. Since all known members of the IL-6 cytokine family induce an hepatic acute phase protein (APP) gene expression, we investigated the ability of CT-1 to induce a liver acute phase response. Upon stimulation of rat hepatoma cells, CT-1 and LIF induced the strongest rat fibrinogen mRNA expression, OSM and IL-6 induced a less pronounced response. When human hepatoma cells and primary rat hepatocytes were stimulated with CT-1, the expression of human haptoglobin a…

medicine.medical_specialtyCarcinoma HepatocellularCardiotrophin 1medicine.medical_treatmentBiophysicsGene ExpressionCiliary neurotrophic factorBiochemistryCardiotrophin 1Structural BiologyInternal medicineGene expressionGeneticsmedicineTumor Cells CulturedAnimalsHumansHepatocyteInterleukin 6Molecular BiologybiologyInterleukin-6Acute-phase proteinCell BiologyMolecular biologyMacroglobulinRatsmedicine.anatomical_structureEndocrinologyCytokineHepatocytebiology.proteinCytokinesInterleukin-6-cytokine familyAcute-Phase ProteinsAcute-phase responseFEBS Letters
researchProduct